NCT00274742View on ClinicalTrials.gov

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 31, 2011

Study Completion Date

April 30, 2012

Conditions
Non-Hodgkin's Lymphoma, Relapsed
Interventions
BIOLOGICAL

Blinatumomab (MT103)

Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion

Trial Locations (5)

45147

Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Essen

72076

Universtätsklinkum Tübingen, Tübingen

89081

Universitätsklinikum Ulm, Abteilung Innere Medizin III, Ulm

91054

Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen

97080

Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg, Würzburg

All Listed Sponsors
lead

Amgen Research (Munich) GmbH

INDUSTRY

NCT00274742 - Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | Biotech Hunter | Biotech Hunter